Key statistics
On Friday, Rhythm Pharmaceuticals Inc (RYTM:NMQ) closed at 52.80, -5.10% below its 52-week high of 55.64, set on Sep 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 54.55 |
---|---|
High | 54.55 |
Low | 52.47 |
Bid | 41.33 |
Offer | 57.00 |
Previous close | 54.55 |
Average volume | 702.93k |
---|---|
Shares outstanding | 61.13m |
Free float | 54.53m |
P/E (TTM) | -- |
Market cap | 3.23bn USD |
EPS (TTM) | -4.37 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- Rhythm Pharmaceuticals Announces New Employment Inducement Grants
- Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old
- Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September
- Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update
- Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old
- Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity
- Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
- Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer
- Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency
- Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
More ▼